Printer Friendly

Articles from The Fly (May 11, 2020)

1-210 out of 210 article(s)
Title Author Type Words
AcelRx reports Q1 EPS (20c), consensus (17c). Financial report 157
AcelRx says Tetraphase co-promotion pact to remain in place regardless of merger. 321
Acer Therapeutics enters research pact with NCATS for emetine hydrochloride. Clinical report 300
Act II Global Acquisition reaffirms Whole Earth brands transaction. 194
Adamis Pharmaceuticals reacquiring rights to SYMJEPI injection. 259
Aimmune says COVID-19 has paused launch of Palfozia. 199
Alico reports Q2 EPS 48c vs. $1.01 last year. Financial report 353
Alkermes expands patient access to Aristada, Vivitrol during COVID-19 pandemic. 155
Amazon buyout may not appeal to AMC shareholders, says B. Riley FBR. 184
Ambac reports Q1 adjusted EPS ($5.75), consensus (53c). 155
American Financial reports Q1 core EPS $1.88, consensus $1.85. Financial report 188
American Shared Hospital reports Q1 EPS (2c) vs. 5c last year. 285
AMN Healthcare sees Q2 revenue $550M-$570M, consensus $610.89M. Financial report 268
Apyx Medical reports Q1 EPS (6c), consensus (25c). Financial report 441
Arbutus Biopharma initiates program to find medicines to treat COVID-19. 244
Arlington Asset Investment reports Q1 corre EPS 17c, consensus 15c. Financial report 270
Arlo Technologies reports Q1 EPS (34c), consensus (35c). Financial report 186
ArTara Therapeutics changes corporate name to Protara Therapeutics. 158
Asian Market Update:. 200
Assertio Therapeutics not providing guidance. 181
AstraZeneca reports Enhertu granted Breakthrough Therapy Designation in U.S. 169
AstraZeneca, Merck announce FDA approval of LYNPARZA/bevacizumab combination. 153
AutoNation provides business update amid COVID-19 pandemic. 239
Avadel Pharmaceuticals reports Q1 EPS (2c), consensus (24c). Financial report 192
Avaya reports Q2 EPS ($7.24) vs. (12c) last year. Financial report 243
Bassett Furniture announces 25% permanent reduction in workforce. 334
Bellerophon announces FDA clearance for initiation of Phase 3 study for INOpulse. Clinical report 365
BlackRock announces secondary offering of shares held by PNC Financial. 156
BlackRock announces secondary offering of shares held by PNC Financial. 154
Bluebird Bio enters strategic agreements with Hitachi Chemical subsidiaries. 152
Bluebird Bio reports Q1 EPS ($3.64), consensus ($4.01). Financial report 247
Bluebird Bio, Bristol-Myers enter amended BCMA CAR-T collaboration agreement. 173
BridgeBio's QED announces preclinical data on low-dose infigratinib. 434
Brighthouse Financial reports Q1 adjusted EPS $2.60, consensus $1.66. Financial report 230
Bristol-Myers to present data from over 50 company-sponsored studies at ASCO20. 179
Cable One sees incurring higher expenses in Q2. 210
Cabot sees lower demand due to impact of COVID-19 to continue. 355
Caesars reports Q1 EPS (36c), consensus (18c). Financial report 229
Callon Petroleum announces actions in response to COVID-19 impact. 219
Cameco restarts production at Ontario operations, Cigar Lake status unchanged. 395
Camtek reports Q1 EPS 9c, consensus 11c. Financial report 179
Castle Biosciences reports Q1 EPS 3c, consensus (15c). Financial report 273
Catalyst Biosciences reports Q1 EPS (28c), two est. (36c). Financial report 167
Cellect Biotechnology announces publication of ApoGraft data in medical journal. 264
CEO of SoftBank-backed Banjo resigns amid reports of KKK ties. 176
China XD Plastics forms special committee to evaluate going private proposal. 179
Choice Hotels not providing FY20 guidance at this time. 184
ChromaDex says COVID-19 impact on revenues difficult to predict. 181
Cleveland-Cliffs reports Q1 revenue inc. deferred $359.1M, consensus $366.23M. Financial report 189
Cleveland-Cliffs sees 'fairly strong' operations in second half. 199
Cocrystal reprioritizes development activities to accelerate COVID-19 program. 621
Consol Energy reports Q1 EPS 9c, consensus 56c. Financial report 170
Continental Resources reports Q1 adj. EPS (8c), consensus 1c. Financial report 186
ContraFect announces four abstracts published in 30th ECCMID abstract book. Clinical report 734
Corbus Pharmaceuticals announces clinical program updates. Clinical report 356
Cornerstone OnDemand names Phil Saunders next CEO. 178
Coty and KKR announce strategic partnership, MOU for KKR to acquire 60% of Wella. 278
COVID testing drives Blair to upgrade Meridian for first time in 10 years. 158
Crispr, Vertex announce FDA RMAT designation granted to CTX001. 224
Cumulus Media reports Q1 EPS (36c), consensus 5c. Financial report 184
CymaBay reports Q1 EPS (19c), consensus (30c). Financial report 241
Daniel Kretinsky's Vesa Equity takes 5% active stake in Macy's. 168
Dare Bioscience, Health Decisions form strategic partnership for novel pipeline. 257
Democrats expect stimulus bill vote no sooner than Friday, WSJ says. 165
Democrats expects stimulus bill vote no sooner than Friday, WSJ says. 165
DermTech says proof-of-concept data published in SKIN. 196
Diodes reports Q1 adjusted EPS 46c, consensus 48c. Financial report 159
Durect working with FDA on Phase 2 study of DUR-928 in COVID-19 patients. 265
Ehang partners with LN Holdings in buileding of UAM theme hotel. 156
EMA recommends expanding compassionate use of Gildead's remdesivir in COVID-19. 189
Endologix completes enrollment in EVAS2 Confirmatory Clinical Study. Clinical report 225
Energy Focus launches EnFocus controlled lighting solutions. 194
Energy Transfer cuts FY20 growth capital outlook to $3.6B. 153
Ensign Group backs FY20 EPS view $2.50-$2.58, consensus $2.46. 166
Enthusiast Gaming forms content creation partnership with ZHU. 307
Essential Properties Realty Trust reports Q1 core FFO 30c, consensus 31c. 169
Ethan Allen provides business update amid COVID-19 pandemic. 284
Ethan Allen reports Q3 adj. EPS 2c, consensus 6c. Financial report 264
Evelo Biosciences expects data readout fro Phase 2 trial in COVID-19 in 2H20. 193
Evelo Biosciences reports Q1 EPS (71c), consensus (75c). Financial report 169
Evelo Biosciences selects enteric capsule formulation o EDP1815 for evaluation. Clinical report 213
Exagen reports Q1 EPS (44c), consensus (49c). Financial report 158
Exterran reports Q1 EPS (56c), two est. (31c). Financial report 259
Fate Therapeutics reports Q1 EPS (44c), consensus (39c). Financial report 174
First Choice Bank appoints Robert Franko as CFO. 186
Fly Intel: Top five analyst downgrades. 245
Fly Intel: Top five analyst downgrades. 245
Fly Intel: Top five analyst upgrades. 254
FTS International announces 1-for-20 reverse stock split. 161
FX Action: The yen pared most of the gains. 350
FX Action: USD-CAD posted an 11-day low. 226
FX Update: The dollar picked up safe haven demand. 247
FX Update: The yen has continued to weaken and commodity currencies strengthen. 317
Galectin Therapeutics expects cash to fund operations through at least Sept. 30. 172
Galectin Therapeutics expects first initiation in NASH-RX trial in 2Q20. 210
Galectin Therapeutics reports Q1 EPS (6c), two est. (9c). Financial report 158
GameStop urges holders to vote in support of its director nominees. 224
Garrett Motion reports Q1 adj. EPS 89c vs. $1.22 last year. Financial report 208
General Mills saw 'unprecedented' rise in food at home demand n March. 395
General Mills sees exceeding FY20 guidance for organic net sales, adjusted EPS. 261
Genesco provides store reopening plan update. 317
Genfit Phase 3 trial of elafibranor in NASH fails to meet endpoint. 293
GNC Holdings reports Q1 adjusted EPS (19c), one estimate 6c. Financial report 202
GNC Holdings says may need to file petition for relief under Chapter 11. 182
GNC Holdings withheld rent, in process of reviewing debt refinancing options. 319
Gold Resource expands Nevada 'Scarlet' target. 299
Governor Cuomo unveils 'NY FORWARD' plan to reopen state after pandemic. 176
Grocery Outlet reports Q1 adjusted EPS 36c, consensus 25c. Financial report 153
GW Pharmaceuticals reports Q1 EPS (2c), consensus (85c). Financial report 155
Hamilton Beach found 'accounting irregularities', files for extension with SEC. 254
Hamilton Beach provides update on operation due to COVID-19. 326
Hamilton Beach says 'company continues to execute key strategic initiatives'. 227
Hamilton Beach sees Q1 revenue down 4%-5% due to COVID-19 impact. 341
Hamilton Beach withdraws FY20 outlook due to COVID-19. 436
Heat Biologics reports continued progres advancing HS-110. 245
Histogen receives IND approval to initiate Phase 1b/2a trial of HST 001. 250
IFF reports Q1 adjusted EPS $1.62, consensus $1.59. Financial report 158
Infinity Pharmaceuticals reports Q1 EPS (19c), consensus (13c). Financial report 311
INmune Bio's says INB03 inhibits cell migration, tumor growth. 166
Inovio reports Q1 EPS (26c), consensus (22c). Financial report 209
Inspire Medical announces release date fro final LCD policy covering therapy. 158
Inter Parfums reports Q1 EPS 32c, consensus 43c. Financial report 322
Intercept reports Q1 EPS ($2.86), consensus ($2.95). Financial report 194
Intercept sees 2020 non-GAAP operating expenses $560M-$600M. 160
Kaman reports Q1 EPS 48c, consensus 32c. Financial report 290
Kandi Technologies to delay 10-Q filing. 300
Kiniksa reports data for mavrilimumab in COVID-19 pneumonia. 323
Kiniksa reports vixarelimab data in diseases characterized by chronic pruritus. Clinical report 277
Kodiak Sciences reports Q1 EPS (54c), consensus (46c). Financial report 425
Kosmos reports Q1 adj. EPS (16c), consensus (15c). Financial report 230
LiqTech announces operational update amid COVID-19 outbreak. 368
LogicBio Therapeutics reports Q1 EPS (41c), consensus (48c). Financial report 176
Magnolia Oil & Gas reports Q1 EPS ($7.34) vs. 8c last year. Financial report 193
Mammoth Energy reports Q1 adj. EPS (36c), two est. (53c). 153
Marriott says there are improving occupancy trends in Greater China. 378
Melody Investment Advisors acquires wireless towers from Uniti. 219
Menlo Therapeutics reports Q1 EPS (95c), consensus (54c). Financial report 188
Mimecast sees FY21 revenue $475M-$485M, consensus $493.48M. 184
Moving away from Fremont could add risk to Tesla manufacturing, says Wedbush. 160
Mylan reports Q1 revenue $2.62B, consensus $2.65B. Financial report 290
Mylan says on track to close pending Upjohn combination in second half. 222
MyoKardia Phase 3 EXPLORER trial meets primary, secondary endpoints. 311
Myriad Genetics receives FDA approval of myChoice CDx as companion for Lynparza. 161
Nemaura Medical announces initial user data from head-to-head CGM comparison. 263
Northern Oil and Gas now sees 2020 CApEx $175M-$200M. 256
Northern Oil and Gas reports Q1 EPS 74c vs. (29c) last year. Financial report 194
Novavax to receive up to $388M funding from CEPI for COVID-19 development. 404
Oasis Midstream Partners postpones Q1 earnings release. Financial report 176
Oasis Petroleum postpones Q1 earnings release. Financial report 173
Obalon not planning to reopen retail stores, reinitiate expansion plans. 498
Omeros reports Q1 adjusted EPS (53c), consensus (34c). Financial report 200
One Group Hospitality provides COVID-19 update. 396
One Group Hospitality reports Q1 EPS (16c), consensus 1c. Financial report 165
OpGen CEO expects top-line revenue to continue to grow in years ahead. 756
OpGen chairman says 'excited' about prospects for the company. 630
Orgenesis reports Q1 EPS $4.23. Financial report 465
Ormat Technologies reports Q1 EPS 51c, consensus 51c. Financial report 189
Oxford Lane sees NAV $2.67-$2.77 as of April 30. 323
Oyster Point Pharma announces ONSET-2 study meets primary, secondary endpoints. 634
Park Hotels & Resorts reports Q1 AFFO 24c, consensus 14c. 255
Passage Bio reports Q1 EPS ($1.00), consensus (45c). 153
PennantPark reports Q1 EPS 18c, consensus 16c. Financial report 153
PepsiCo announces new direct-to-consumer offerings. 278
Perma-fix Environmental awarded 2 contracts valued at $3.7M by federal client. 200
Playa Hotels & Resorts reports Q1 EPS 2c, consensus 14c. Financial report 184
PNC Financial announces intent to sell investment in BlackRock. 169
Protalix: BRIDGE study successfully met main safety, efficacy objectives. 287
PulteGroup povides COVID-19 update, announces furloughs, layoffs. 337
Purple says demand accelerated sharply in the first weeks of April. 212
Quaker Houghton reports Q1 adjusted EPS $1.38, consensus $1.10. Financial report 174
Quaker Houghton sees FY20 adjusted EBITDA over $200M. 225
Quanterix announces Simoa platform used in development of COVID-19 antibody test. 290
Recro Pharma lowers 2020 revenue view $80M-$85M from $97M-$100M. 433
Recro Pharma says production, shipping functions remain operational. 258
Regeneron, CCPM announce human genetics research collaboration. 188
Researcher finds security flaw in PCs with Intel Thunderbolt port, CRN reports. 157
Revlon reports Q1 EPS ($4.02), one estimate ($1.07). 177
Ritter Pharmaceuticals regains compliance with Nasdaq requirement. 171
RMR Group reports Q1 EPS 39c, consensus 49c. Financial report 242
Rockwell Medical reports Q1 EPS (12c), consensus (12c). Financial report 229
Rocky Mountain Chocolate suspends quarterly dividend amid COVID-19 pandemic. 291
Sarepta, Dyno Therapeutics to develop gene therapy vectors for muscle diseases. 179
Scorpio Bulkers reports Q1 adj. EPS ($15.65), consensus ($2.02). Financial report 166
SEACOR Marine Holdings reports Q1 EPS (66c), one est. (62c). Financial report 277
Sientra reports Q1 EPS (57c), consensus (49c). Financial report 164
Soligenix announces RiVax immunogenicity studies published. 252
SSR Mining, Alacer Gold announce at-market merger of equals. 295
Stage Stores commences voluntary Chapter 11 process. 568
Starboard delivers open letter to GCP Applied Technologies shareholders. 479
Sunoco LP reports Q1 net loss ($128M) vs. ($109M) a year ago. Financial report 202
Synchronoss reports Q1 EPS (29c), consensus (42c). Financial report 226
TearLab to be acquired by Accelmed Partners II, taken private. 222
Tilray says has not experienced material COVID-19 impacts. 231
Tracon Pharmaceuticals reaches agreement with FDA on elements of ENVASARC trial. Clinical report 154
Treasury Action: the historically large $96 B May refunding kicks off today. 154
Treasury Action: the market is cheapening ahead of the record $42 B 3-year sale. 160
Treasury Market Outlook: equities are slumping. 221
Treasury's upsized $117 B (was $111 B) 3- and 6-month bill auctions were well received. 226
Twitter rolls out new warning messages for misleading information on COVID-19. 198
U.S. equity futures are weaker. 235
Under Armour reports Q1 adjusted EPS (34c), consensus (18c). Financial report 154
Usio reports Q1 credit card dollars processed up 21%. 194
Vera Bradley expects to open stores in phased approach. 380
Victory Capital reports Q1 adj. EPS 92c, consensus 89c. Financial report 351
Vuzix reports Q1 EPS (18c), two estimates (16c). Financial report 203
Wave Life Sciences provides update on PRECISION-HD programs. 276
Wave Life Sciences reports Q1 EPS ($1.38), consensus ($1.20). Financial report 207
Xenia Hotels reports Q1 AFFO 17c, consensus 8c. 418
YRC Worldwide reports Q1 EPS 13c, consensus (57c). 251
Zimmer Biomet reports Q1 adj. EPS $1.70, consensus $1.35. Financial report 159

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters